Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06846398 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 in Adult Subjects With Hereditary Angioedema
A Phase 2 study of Hereditary Angioedema (HAE), sponsored by Shanghai Argo Biopharmaceutical Co..
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 18
- Study locations
NCT06846398 is a Phase 2 study of Hereditary Angioedema (HAE) that is active but no longer recruiting, run by Shanghai Argo Biopharmaceutical Co.. The registered enrollment target is 25 participants, below the 64-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (61% lower). The trial reports 18 study locations across 18 states.
The verdict
NCT06846398, a Phase 2 study of Hereditary Angioedema (HAE), is active but no longer recruiting, sponsored by Shanghai Argo Biopharmaceutical Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 18
- Study locations
Study Summary
A Phase 2 in Adult Subjects with Hereditary Angioedema
Conditions Studied
Interventions
- DRUG BW-20805
Study Locations (18)
Maryland
- Institute for Asthma and Allergy - Wheaton - Silver Spring
Missouri
- Washington University School of Medicine - St Louis
North Carolina
- Duke University Medicine Center - Durham
Pennsylvania
- Penn State Milton S. Hershey MC - Penn State - Hershey
Virginia
- Inova Clinical Trials and Research Center - Falls Church
Beijing Municipality
- Peking Union Medical College Hospital - Beijing
Gansu
- The First Hospital of Lanzhou University - Lanzhou
Hubei
- Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology - Wuhan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2028-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06846398
The ClinicalTrials.gov registry entry for NCT06846398 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (61% lower). The listed sponsor is Shanghai Argo Biopharmaceutical Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Angioedema (HAE) appearing as the primary indexed condition, and to 1 intervention - of which BW-20805 is the first listed.
NCT06846398 reports 18 study locations spanning 18 distinct geographic areas - top geographies include Maryland, Missouri, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06846398 about?
NCT06846398 is a clinical study titled "A Phase 2 in Adult Subjects With Hereditary Angioedema". A Phase 2 in Adult Subjects with Hereditary Angioedema
What is the current status of trial NCT06846398?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-02-28. Estimated completion is 2028-03-30.
What conditions does trial NCT06846398 study?
This clinical trial studies the following conditions: Hereditary Angioedema (HAE).
What interventions are being tested in trial NCT06846398?
The interventions under investigation include: BW-20805 (DRUG).
Who is sponsoring clinical trial NCT06846398?
This trial is sponsored by Shanghai Argo Biopharmaceutical Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06846398 being conducted?
This trial has 18 study locations across Maryland, Missouri, North Carolina, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema (HAE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
COMPLETED · Phase 2
-
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
RECRUITING · Phase 1
-
A Study of Navenibart in Participants With Hereditary Angioedema
RECRUITING · Phase 3
-
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
RECRUITING · Phase 3
-
Donidalorsen Treatment in Children With Hereditary Angioedema
RECRUITING · Phase 3
-
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.